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Abstract
Introduction Guidelines recommend endoscopy with biopsies to stratify patients with gastric premalignant lesions (GPL) to 
high and low progression risk. High-risk patients are recommended to undergo surveillance. We aimed to assess the accuracy 
of guideline recommendations to identify low-risk patients, who can safely be discharged from surveillance.
Methods This study includes patients with GPL. Patients underwent at least two endoscopies with an interval of 1–6 years. 
Patients were defined ‘low risk’ if they fulfilled requirements for discharge, and ‘high risk’ if they fulfilled requirements for 
surveillance, according to European guidelines (MAPS-2012, updated MAPS-2019, BSG). Patients defined ‘low risk’ with 
progression of disease during follow-up (FU) were considered ‘misclassified’ as low risk.
Results 334 patients (median age 60 years IQR11; 48.7% male) were included and followed for a median of 48 months. At 
baseline, 181/334 (54%) patients were defined low risk. Of these, 32.6% were ‘misclassified’, showing progression of disease 
during FU. If MAPS-2019 were followed, 169/334 (51%) patients were defined low risk, of which 32.5% were ‘misclas-
sified’. If BSG were followed, 174/334 (51%) patients were defined low risk, of which 32.2% were ‘misclassified’. Seven 
patients developed gastric cancer (GC) or dysplasia, four patients were ‘misclassified’ based on MAPS-2012 and three on 
MAPS-2019 and BSG. By performing one additional endoscopy 72.9% (95% CI 62.4–83.3) of high-risk patients and all 
patients who developed GC or dysplasia were identified.
Conclusion One-third of patients that would have been discharged from GC surveillance, appeared to be ‘misclassified’ as 
low risk. One additional endoscopy will reduce this risk by 70%.
Keywords Surveillance · Prevention · Gastric cancer · Atrophic gastritis · Intestinal metaplasia
Abbreviations
CAG  Chronic atrophic gastritis
GC  Gastric cancer
GPL  Gastric premalignant lesions
HGD  High-grade dysplasia
IM  Intestinal metaplasia
LGD  Low-grade dysplasia
MAPS  Management of precancerous conditions and 
lesions in the stomach
BSG  British society of gastroenterology
OLGIM  Operative link on gastric intestinal metaplasia
Introduction
Prognosis of advanced gastric cancer is poor, with a five-
year-survival rate of 20% [1]. However, if gastric cancer 
is detected at an early stage, survival rates improve up to 
90% [2, 3]. Chronic atrophic gastritis (CAG) and intestinal 
metaplasia (IM) are precursor lesions of gastric adenocar-
cinoma (GC) [4]. These premalignant lesions make gastric 
cancer suitable for screening and surveillance, depending 
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on the regional prevalence of (pre-)malignant lesions and 
progression rates to cancer. Nationwide screening strate-
gies are mainly relevant for high-GC prevalence regions 
such as East-Asia, where population-based screening pro-
grams are implemented [5]. In case advanced premalignant 
lesions are detected, patients are eligible for surveillance 
and early intervention when possible [6]. For regions with 
low prevalence rates, such as Western Europe and North 
America, nationwide screening is not recommended due to 
a low a priori risk. However, when patients of these regions 
are inadvertently diagnosed with advanced premalignant 
lesions, for instance, during routine endoscopy, surveillance 
should be considered given the risk of progression to cancer. 
The debate about the balance between harms and benefits of 
surveillance strategies is still ongoing [7]. To this end, US 
guidelines state that surveillance is not indicated except for 
individuals with a known increased gastric cancer risk, such 
as persons of Asian ancestry or patients with a positive fam-
ily history [8]. European MAPS (management of epithelial 
precancerous conditions and lesions in the stomach) as well 
as the British guidelines, recommend surveillance in patients 
with a premalignant gastric lesion [9–11]. These surveil-
lance recommendations depend on the extent and severity 
of these premalignant lesions. The MAPS-2012 guideline 
recommended surveillance for patients with extensive CAG 
or IM. In the updated MAPS-2019 guideline, surveillance 
was extended to patients with CAG and IM limited to either 
the antrum or the corpus and presence of incomplete intesti-
nal metaplasia (in any of the biopsies), autoimmune gastritis, 
persistent Helicobacter pylori (H. pylori) infection or a first 
degree relative with gastric cancer. In 2019, the British Soci-
ety of Gastroenterology also published a guideline (BSG) 
on the management of gastric premalignant lesions. The 
recommendations on surveillance of premalignant lesions 
were mostly identical to the revised MAPS-2019 guideline. 
The only difference with the MAPS guideline is that patients 
with autoimmune gastritis and CAG or IM limited to the 
antrum or corpus were not referred for further surveillance.
To assess the extent and severity of premalignant gas-
tric lesions, endoscopic surveillance is advised. However, 
endoscopic recognition of gastric premalignant lesions can 
be difficult. Therefore, obtaining random biopsies through-
out the stomach according to the updated Sydney protocol 
is recommended [12]. Nevertheless, due to the uneven dis-
tribution of gastric premalignant lesions, random biopsies 
may not properly reflect the extent of the lesions and subse-
quently the individual gastric cancer risk [13]. Since only a 
few patients will develop gastric cancer, it is essential that 
surveillance strategies in practice lead to the identification 
of those few cases. While the addition of new risk factors to 
the MAPS-2019 and BSG potentially allows better stratifi-
cation of at-risk patients, thus far, there is only limited data 
describing to what extent we can accurately dismiss patients 
with premalignant gastric lesions from surveillance, based 
on their low risk of gastric cancer development. The aim of 
this study was to assess to what extent we can accurately 
identify low-risk patients who can safely be discharged from 
gastric surveillance according to the recommendations of 
MAPS-2012, MAPS-2019 and BSG guideline.
Methods
Study design
This study is based on the Proregal study (Progression and 
Regression of precancerous Gastric Lesions). The design of 
the study has been described previously [14]. In short, this 
study was initiated in 2009 and is an ongoing prospective 
cohort study carried out in six hospitals (one academic, five 
regional) in the Netherlands and one regional hospital in 
Norway. Patients are eligible for inclusion if they are over 
18 years of age and diagnosed with one of the following 
conditions at routine endoscopy (t0): atrophic gastritis, intes-
tinal metaplasia and/or dysplasia in any part of the gastric 
mucosa. Patients are excluded from participation if they 
have: (1) previously undergone upper gastrointestinal sur-
gery, (2) a previous diagnosis of gastric carcinoma, or any 
other malignancy not being in remission, (3) severe comor-
bidity limiting their expected survival to less than 2 years, 
(4) portal hypertension, or (5) a proven CDH1 mutation. 
In case H. pylori was present, H. pylori eradication was 
provided, and eradication was verified. in all patients (20 
patients had persistent H. pylori colonization). H. pylori 
eradication was eventually achieved in all patients.
In all subjects, a surveillance endoscopy is performed 
at one (t1) and three (t2) years after the initial endoscopy. 
Random biopsy samples are obtained according to the Prore-
gal biopsy protocol with targeted biopsies in case of visible 
gastric lesions (Fig. 1).
In case of low-grade dysplasia (LGD) or high-grade 
dysplasia (HGD), the surveillance interval is shortened to 
twelve and six months, respectively. In case a visible lesion 
is detected, endoscopic resection of the lesion is performed. 
After t2, continuation or cessation of surveillance is decided 
based on the recommendations of the MAPS guideline. For 
the purpose of this study, subjects who were discharged from 
further surveillance based on the MAPS guideline recom-
mendation at t2 were re-invited for endoscopy (t3).
Patient selection
All patients from the Proregal cohort were eligible for 
inclusion provided patients had at least one follow-up 
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endoscopy. Patients were classified as low or high risk. 
Low-risk patients were defined as patients with premalig-
nant gastric lesions, who do not fulfil the requirements for 
surveillance (i.e. IM limited to the antrum). ‘High risk’ 
patients are patients with premalignant gastric lesions who 
are advised to undergo surveillance (i.e. IM in both antrum 
and corpus). Requirements for surveillance are described 
in more detail in Supplementary Table 1.
At baseline, patients were defined as ‘low risk’ for 
progression of disease if they fulfilled requirements for 
discharge based on the European guidelines MAPS-2012, 
MAPS-2019 or the BSG guideline. Patients were defined 
as ‘high risk’ if further surveillance was indicated accord-
ing to these guidelines.
To assess the safety of discharging patients from further 
surveillance based on MAPS/BSG guideline recommenda-
tions, we included the ‘low risk’ patients who had no indi-
cation for further surveillance according to the guidelines 
at t1 or t2 (e.g. limited extension of IM), but underwent a 
surveillance endoscopy within the scope of this study. We 
correlated the findings with the outcome of the endoscopy 
performed at t2 and t3, respectively. In case lesions were 
found at the follow-up endoscopy for which surveillance 
is recommended, the patient was defined as ‘misclassified’ 
as low risk for gastric cancer development.
Furthermore, we linked all patients to the Netherlands 
Cancer Registry, managed by the Netherlands Comprehen-
sive Cancer Organisation (IKNL) to account for all (inter-
val) gastric cancers even after surveillance was stopped. 
Since 1989, the Netherlands Cancer Registry registers all 
participants diagnosed with cancer in the Netherlands. 
The study design is depicted in Fig. 2. The study pro-
tocol was approved by the Institutional Review Board 
(MEC-2009-090).
MAPS‑2012
The MAPS guideline recommendations were first published 
in 2012 [9]. Chronic atrophic gastritis (CAG) or intestinal 
metaplasia (IM) confined to the antrum did not require fur-
ther surveillance. CAG or IM in both antrum and corpus or 
only in the corpus required endoscopic surveillance every 
three years (Suppl. Table 1).
MAPS‑2019
The MAPS guideline recommendations were updated in 
2019 [10]. CAG or IM limited to the antrum or corpus does 
not require further surveillance. However, surveillance every 
three years is recommended if the subject meets one of the 
following criteria: first degree family history of gastric can-
cer, autoimmune gastritis, persistent H. pylori infection or 
incomplete IM (Table 1). Surveillance every 1–2 years is 
recommended in case of a first degree relative with GC 
(Suppl. Table 1).
BSG
The BSG guideline recommendations were published 
in 2019 [11]. In this guideline, CAG or IM limited to the 
antrum or corpus does not require further surveillance. How-
ever, surveillance every three years is recommended if the 
subject meets one of the following criteria: first degree fam-
ily history of gastric cancer or persistent H. pylori infection 
(Table 1).
Statistical analyses
Baseline characteristics are presented as mean with stand-
ard deviation (SD) or median with interquartile range (IQR) 
when appropriate. Kaplan–Meier curves were performed 
on the proportion of patients identified as still at risk after 
Fig. 1  Locations of standardised random gastric biopsies obtained 
during endoscopy for this study
Fig. 2  Flowchart of the study design. GC gastric cancer; HGD high-
grade dysplasia; LGD low-grade dysplasia; MAPS management of 
precancerous conditions and lesions in the stomach; Proregal pro-
gression and regression of precancerous lesions
 M. C. Mommersteeg et al.
1 3
(supposed) discharge of surveillance per year and per endos-
copy for MAPS-2012, MAPS-2019 and BSG guidelines.The 
analyses were performed using SPSS v.24 statistical package 
(SPSS Inc, Chicago, IL).
Results
Patient characteristics
In total, 334 patients were included. Median age was 
60 years (IQR 11) and 48.7% were men. This cohort cap-
tured seven cases of dysplasia or gastric cancer. Baseline 
characteristics of the entire cohort are shown in Table 1 and 
were described in more detail previously [14].
Following the MAPS‑2012 guideline 
recommendation
At baseline, 153/334 (45.8%) patients were correctly 
defined as high risk (i.e. already fulfilled the criteria for 
surveillance according to the guideline) and therefore 
excluded. Of the remaining 181 low-risk patients (i.e. 
would have been discharged from further surveillance 
according to the guideline), 59 patients (32.6%) were 
misclassified as low risk because they had gastric lesions 
at subsequent endoscopies that gave reason to continue 
surveillance (i.e. gastric premalignant lesions not limited 
to the antrum) see also Fig. 3a. This included four out of 
the total seven cases of LGD/HGD/gastric cancer cases. 
LGD was found in one patient, HGD was found in two 
patients, and one patient developed gastric cancer. One of 
the patients with HGD underwent endoscopic resection 
and died from causes unrelated to gastric cancer or the 
procedure. The other patient with HGD underwent a suc-
cessful gastrectomy. The patient with gastric cancer and 
the patient with LGD underwent an endoscopic resection 
and are currently in remission for over two years. Patient 
characteristics of these cases are available in Table 2.
Following the MAPS‑2019 guideline 
recommendation
At baseline, 165/334 (49.4%) patients were correctly defined 
as high risk (i.e. already fulfilled the criteria for surveillance 
according to the guideline) and therefore excluded. Of the 
remaining 169 low-risk patients (i.e. would have been dis-
charged from further surveillance according to the guide-
line), 55 patients (32.5%) were misclassified as low risk 
because they had gastric lesions at subsequent endoscopies 
that gave reason to continue surveillance (i.e. gastric pre-
malignant lesions not limited to the antrum). This included 
three out of the total seven cases of LGD/HGD/gastric can-
cer (one case of LGD, HGD and gastric cancer each) see 
also Fig. 3b. These patients were also misclassified by the 
MAPS-2012 guideline. The correctly classified patient with 
HGD (that was misclassified in MAPS-2012) was included 
for surveillance according to MAPS-2019 because of a first 
degree relative with gastric cancer. This patient had HGD, 
but declined further therapy due to comorbidities and age, 
although (endoscopic) resection might have been possible. 
Another patient with carcinoma who would have been dis-
charged according to the extent of his lesions (limited to the 
corpus) was recommended to undergo surveillance accord-
ing to the MAPS-2019 guideline, also because of a first 
degree relative with gastric cancer. Patient characteristics 
of these cases are depicted in Table 2.
Following the BSG guideline recommendation
At baseline, 160/334 (47.9%) patients were correctly defined 
as high risk (i.e. already fulfilled the criteria for surveil-
lance according to the guideline) and therefore excluded. 
Of the remaining 174 low-risk patients (i.e. would have 
Table 1  Baseline characteristics of the total Proregal cohort
H. pylori Helicobacter pylori; IQR inter quartile range; GC gas-
tric cancer; HGD high-grade dysplasia; LGD low-grade dysplasia; 
OLGIM operative link on gastric intestinal metaplasia assessment; 
Proregal cohort total number of the prospective cohort that are or 
have been under surveillance for their gastric premalignant lesions




Gender (male, %) 48.7
Age (median, IQR) 60 (11)
H. pylori positive (histology) 103 (31)
Follow-up months (median, IQR) 48 (24)
Most severe lesion recent  endoscopya
 OLGIM 0 123 (36)
 OLGIM I 55 (16)
 OLGIM II 81 (24)
 OLGIM III 51 (15)






 Persistent H. pylori infection 20
 Autoimmune gastritis 20
 First degree family history of GC 47
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been discharged from further surveillance according to the 
guideline), 56 patients (32.2%) were misclassified as low 
risk because they had gastric lesions at subsequent endos-
copies that gave reason to continue surveillance (i.e. gas-
tric premalignant lesions not limited to the antrum). This 
included three out of the total seven cases of LGD/HGD/
gastric cancer (one case of LGD, HGD and gastric cancer 
each) see also Fig. 3c. These patients were also misclas-
sified by the MAPS-2012 and MAPS-2019 guideline. The 
correctly classified HGD patient (who was misclassified in 
MAPS-2012) was included for surveillance according to 
BSG because of a first degree relative with gastric cancer. 
This patient had HGD, but declined further therapy due to 
comorbidities and age, although (endoscopic) resection 
might have been possible. Another patient with carcinoma 
who would have been discharged according to the extent 
of his lesions (limited to the corpus) was recommended to 
undergo surveillance according to the BSG guideline, also 
because of a first degree relative with gastric cancer. Patient 
characteristics of these cases are depicted in Table 2.
Longitudinal follow‑up
Figure 4 shows a graphical presentation of the results of 
each endoscopy according to the MAPS-2019 guideline. As 
can be appreciated from this figure, several patients con-
tinuously switch between high and low risk of progression. 
The number of endoscopies or time necessary to correctly 
identify low-risk patients was visualized by a Kaplan–Meier 
curve. As seen in Fig. 5a, c, e, one additional endoscopy 
identifies over 75.4% (95% CI 64.3–86.6), 72.9% (95% CI 
62.4–83.3) and 73.2% (95% CI 59.7–84.2) of high-risk 
patients according to the MAPS-2012, MAPS-2019 or BSG 
guideline, respectively. After two additional endoscopies, 
this percentage increases to 89.5% (95% CI 81.5–97.5), 
85.7% (95% CI 77.5–93.9) and 85.7 (95% CI 73.8–93.6 or 
Table 2  Characteristics of patients identified with a resectable lesion in the complete proregal cohort including which guideline would have 
accurately identified these patients being at risk
GPL gastric premalignant lesion; MAPS management of precancerous conditions and lesions in the stomach; BSG British society of Gastroenter-
ology guideline; N/A not applicable; GC gastric cancer; AI autoimmune
a Patient is deceased
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3 64 Female 2009 None Slight intestinal 
metaplasia of 
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4 77 Male 1996 MAPS-2019
BSG
Chronic gastri-










5 46 Male 2008 MAPS-2019
MAPS-2012
BSG








6 53 Female 2009 MAPS-2012
MAPS-2019
BSG






7 72a Male 2006 MAPS-2012
MAPS-2019
BSG
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BSG, respectively. Figure 5b, d, f shows patients who were 
defined as low risk according to MAPS-2012, MAPS-2019 
or BSG by years of follow-up. After 3 years, the percentage 
of correctly identified patients at low gastric cancer devel-
opment risk is 77.2% (95% CI 66.3–88.1), 80.9% (95% CI 
74.1–91.7) and 80.4% (95% CI 67.6–89.8) as shown in 
Fig. 5b, d, f. In this period, all patients underwent either 
one or two additional endoscopies. All of the misclassified 
low-risk patients, who were diagnosed with GC or dysplasia 
during follow-up, would have been correctly classified as 
high risk in case one additional endoscopy between two and 
four years was performed (following any guideline).
Discussion
To the best of our knowledge, this is the first study that 
evaluates how accurate we can identify low-risk GPL 
patients, and whether they can be safely discharged from 
further surveillance based on guideline recommendations. 
Due to the addition of several risk factors in MAPS-2019 
and BSG as compared to MAPS-2012, MAPS-2019 and 
BSG improve the identification of high-risk patients who 
develop lesions requiring treatment, while reducing the 
amount of patients under surveillance. Nevertheless, a large 
proportion of patients at risk of neoplastic progression are 
still missed. Up to 32% of patients who are discharged from 
gastric cancer surveillance appeared to be misclassified as 
‘low risk’ on subsequent endoscopy, including three out 
of the total of seven HGD/GC cases following the current 
European guidelines (MAPS-2019 and BSG). By adding one 
additional endoscopy, all patients who developed dysplasia 
or cancer were correctly identified as high risk and risk of 
misclassification was reduced by 72.9%. Dismissing patients 
from further surveillance after two ‘negative’ endoscopies is 
already common practice in colonic polyp surveillance and 
might be considered in the setting of gastric premalignant 
lesions [15].
Currently, extension and severity of gastric premalignant 
lesions are determined by upper endoscopy with random 
biopsies. This might cause sampling error and with that, 
underestimation of the true extent of lesions [16, 17]. This 
could explain the number of patients who were misclassified 
as low risk in our study, based on the subsequent endoscopy 
results. It has been described previously that conventional 
white light endoscopy (WLE) findings do not correlate well 
to histological findings in gastric premalignant lesions [18, 
19]. Advanced endoscopic techniques such as high-defini-
tion endoscopes and imaging enhancement technologies 
have improved markedly in the past years [20, 21]. High-
Definition-White Light Endoscopy (HD-WLE) has improved 
the correlation between endoscopic and histological diagno-
sis, with a sensitivity ranging between 75% and 92.7% and a 
specificity ranging between 92.7% and 100% [20, 21]. How-
ever, when measured in daily clinical practice, this accuracy 
decreases to 53% sensitivity and 98% specificity [22]. The 
addition of Narrow band imaging (NBI) to high-resolution 
endoscopy can further enhance accuracy up to a sensitivity 
of 85% and a specificity of 77% [23]. Our study highlights 
the importance of embracing and further investigating endo-
scopic improvement tools to stratify at-risk individuals with 
better accuracy and make surveillance guidelines more effi-
cient [23]. These improvements in endoscopic techniques 
opens possibilities for targeted biopsies during surveillance 
endoscopies, which is expected to lower sampling error. On 
the other hand, improvements in endoscopic techniques will 
Fig. 4  Heat map of the outcomes of the PROREGAL study, based 
on MAPS-2019 guideline. On the Y-axis, all individual patients have 
been plotted, on the X-axis, the endoscopies are shown. A green col-
our indicates that MAPS-2019 would not recommend an endoscopy, 
an orange colour represents a recommendation of surveillance. A red 
colour represents detection of lesions that should be considered for 
(endoscopic) resection (i.e. LGD, HGD, gastric adenocarcinoma). 
Several patients who would have been discharged based on the lesion 
found and according to MAPS-2019 guideline did show lesions war-
ranting surveillance in subsequent endoscopies
Fig. 3  Schematic visualization of surveillance of patients with pre-
malignant gastric lesion according to the MAPS-2012 guideline (a), 
according to the MAPS-2019 guideline (b) and according to the BSG 
(c). LGD low-grade dysplasia; HGD high-grade dysplasia; GC gas-
tric cancer; CI confidence interval; MAPS management of precancer-
ous conditions and lesions in the stomach; Proregal progression and 
regression of precancerous lesions
◂
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Fig. 5  Kaplan–Meier analysis of the probability of patients being 
misclassified as low risk for gastric cancer. a Patients who were 
misclassified as low risk according to MAPS-2012, distinguished 
by number of endoscopies needed until identified as still at risk. 
b Patients who were misclassified as low risk according to MAPS-
2012, distinguished by years of follow-up until identified as still 
at risk. c Patients who were misclassified as low risk according to 
MAPS-2019, distinguished by number of endoscopies needed until 
identified as still at risk. d Patients who were misclassified as low risk 
according to MAPS-2019, distinguished by years of follow-up until 
identified as still at risk. e Patients who were misclassified as low risk 
according to BSG, distinguished by number of endoscopies needed 
until identified as still at risk. f Patients who were misclassified as 
low risk according to BSG, distinguished by years of follow-up until 
identified as still at risk. No. number of; FU follow-up; MAPS man-
agement of precancerous conditions and lesions in the stomach
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only lead to a decrease in sampling error if endoscopist is 
trained to correctly interpret endoscopic images and identify 
the gastric lesions. MAPS-2019 guidelines recommend the 
use of NBI or chromoendoscopy as it outperforms the use 
of WLE alone as described above. However, the use of other 
virtual chromoendoscopy such as i-Scan or FICE is less well 
investigated. These new developments may contribute to a 
better detection of premalignant gastric lesions, but therefore 
further research is necessary, especially to assess the usabil-
ity and yield in daily practice in non-expert hands before 
recommendations can be made.
Another potential explanation for the apparent changes in 
perceived severity of lesions during follow-up is that it rep-
resents regression of lesions, rather than sampling error. H. 
pylori eradication effectively blocks progression of intestinal 
metaplasia and reduces the risk of gastric cancer [24]. While 
regression of (chronic) atrophic gastritis has been suggested 
[25–27], actual regression or disappearance of IM has only 
been described in several individual studies. Indeed, several 
meta-analyses show no significant regression of IM even 
after H. pylori eradication and long-term treatment with 
a Cox2 inhibitor [28, 29]. This held true for premalignant 
lesions in all the different locations of the stomach and sup-
ports the idea that sampling error contributes more to the 
fluctuating severity of lesions in our cohort than biological 
pro- or regression of disease [29, 30]. This raises the ques-
tion whether histology from the last available endoscopy 
only is sufficient to identify patients who are at risk for gas-
tric cancer development. According to our data, perform-
ing one additional endoscopy will identify the majority of 
patients who otherwise would have been inappropriately 
discharged. A surveillance strategy in which longitudinal 
data of all previous endoscopies are taken into account in 
risk assessment should be a future step.
The main challenge of surveillance strategies, especially 
in low-risk areas, is to identify the small proportion of 
patients that will benefit from surveillance while circum-
venting the burdens of such strategy. No surveillance strat-
egy will perfectly identify all patients at risk. Therefore, it 
is important to take into account the risk of progression of 
premalignant lesions, the availability of a relatively safe and 
effective method to treat (early) cancers and the burden due 
to surveillance for both patient as well as health care. In 
three (43%) out of the seven patients who developed gas-
tric cancer or dysplasia, at least one high-risk feature was 
present. Our study shows that the addition of risk factors 
(autoimmune gastritis, first degree family history and per-
sistent H. pylori infection) in MAPS-2019 and BSG indeed 
increases the yield of the current surveillance strategy and 
highlights the importance of continuing this improvement 
of risk stratification.
Several limitations have to be taken into account. First, 
this is an observational study which is not powered to 
make specific recommendations to improve current guide-
lines. This study solely provides descriptive information. 
Larger sample size in a randomized controlled trial set-
ting would be needed to truly investigate the risk of mis-
classification and improve on guideline recommendations 
regarding biopsy strategies and surveillance (intervals). 
Furthermore, misclassification of patients is unavoidable 
and what percentage is deemed acceptable is debatable. 
This will depend on the costs health systems are willing 
to bear. Also, even though (almost) half of the dyspla-
sia/gastric cancer cases in our cohort would never have 
received a surveillance endoscopy if guidelines were fol-
lowed, these patients may have presented themselves when 
complaints would have arisen. Inevitably, this would have 
caused some delay in their treatment. However, the pos-
sibility of endoscopic treatment and outcome can only be 
speculated upon.
In conclusion, cancer detection improved with the 
updated MAPS-2019 and BSG guidelines, however, still 
three out of seven dysplasia/GC cases were missed. Fur-
thermore, one-third of patients were misclassified as low 
risk for gastric cancer development and therefore would 
have inappropriately been discharged from further surveil-
lance. The majority of these patients could be identified by 
performing one additional endoscopy within three years. 
Our study emphasizes the need for further improvement 
of stratifying at-risk individuals and improved endoscopic 
recognition of premalignant gastric lesions.
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